Godavari Drugs Hits New 52-Week Low at Rs. 78.3 Amid Ongoing Decline

Godavari Drugs, a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs. 78.3 today, November 12, 2025. This decline marks a significant downturn for the stock, which has seen a 33.76% decrease in value over the past year, contrasting sharply with the Sensex's positive performance of 7.45% during the same period.
Despite today's performance, where Godavari Drugs outperformed its sector by 1.62%, the stock has been on a downward trajectory, experiencing six consecutive days of decline before a slight recovery. The intraday high for the stock was Rs. 82.5, reflecting a modest gain of 2.48%, while it also touched an intraday low of Rs. 78.3, down 2.73%.

The company's financial health has raised concerns, with a high Debt to EBITDA ratio of 3.27 times and negative results reported for the last three consecutive quarters. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a challenging market position. As Godavari Drugs navigates these financial hurdles, its performance metrics suggest a need for strategic reassessment.